GlassScriptPhysician profile
Mara Bactad
NPI 1164157913
$2,559.82
in general payments reported to CMS, 2019-2025
15 companies · $968 in 2025
The $968 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $40.02 · 2023: $483 · 2024: $1,069 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,488 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,487.53 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $773.16 | 2022-2025 | Farxiga, Lokelma, Breztri |
| Amgen INC. | $328.55 | 2023-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $276.55 | 2023-2025 | Sapien 3 Ultra Resilia |
| Novartis Pharmaceuticals Corporation | $211.05 | 2022-2024 | |
| Novo Nordisk INC | $186.51 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Genzyme Corporation | $143.40 | 2023-2024 | |
| Medtronic, INC. | $126.12 | 2024 | Corevalve Evolut R |
| Bayer Healthcare Pharmaceuticals INC. | $125.43 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.27 | 2023-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $107.31 | 2025 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $78.13 | 2024 | Arcalyst |
| Abiomed | $29.65 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $22.97 | 2025 | Eliquis |
| Kiniksa Pharmaceuticals, LTD. | $15.71 | 2023 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.01 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mara Bactad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.